China’s Biggest Biologics CDMO Becoming a Global Leader

WuXi Biologics is a young biologics contract development and manufacturing organization, or CDMO. It is rapidly building up capacity to become comparable in size to the top three players. It is the largest biologics CDMO in China and the third largest globally. WuXi is growing at an explosive rate, is already well positioned in China, and is in the process of establishing its global brand. WuXi reported CNY 10.3 billion of revenue in 2021 and a three-year CAGR of 60%. Revenue by geography was 51% from North America, 24% from China, and 22% from Europe. About 33% of its projects are pre-IND (that is prior to clinical testing).